Company Profile

ConTIPI Medical

ConTIPI Medical develops non-invasive and disposable vaginal devices for women with Pelvic Floor Disorders. All devices are inserted vaginally by the user herself, at her home environment, within a disposable applicator. Within the vagina the device opens to provide support. By the end of use, or at the user’s will, a pull of a string collapses the device back into small dimensions, for disposal.
Initial device, for management of stress urinary Incontinence, was sold to Kimberly Clark Worldwide Inc, and is already for sale in North America under the name Poise Impressa.

Current solution, for Pelvic Organ Prolapse, the ProVate Device, which follows the same concept, is ready for the market, has a CE Mark, and is now under regulatory consideration in the US.

Ferring Pharmaceuticals

Ferring Pharmaceuticals is a Swiss-based, research-driven, specialty biopharmaceutical group committed to helping people live better lives. Founded in 1950, it is a leader in reproductive medicine/women’s health, and in specialty areas within gastroenterology and urology. Ferring employs more than 6,500 people and markets its products in 110 countries, and acquired Bio-Technology General (BTG) with its biotech capabilities in 2005.

In Israel, Ferring Holding Ltd. (FHL) plays a pivotal role in Ferring’s global innovation activities. Founded in 2016, FHL collaborates with local academics, physicians and entrepreneurs to deliver life-changing biopharmaceuticals and medical technologies. Its goal is to foster local innovations in biotechnology and other disciplines, including new areas such as mobile health, in Ferring’s key therapeutic areas.


Gynica is changing the culture of gynecological treatment through clinically-proven, cannabinoid-based solutions.

Gynica is a medical company at the forefront of therapeutic cannabis research in the field of women’s health. Our team develops medical treatments based on innovative technology and an advanced understanding of the pharmacological effects of cannabinoids that target specifically female symptoms and diseases.

We believe that cannabinoids are the missing piece in the treatment of gynecological disorders –

Scientific research has shown that the cannabis plant is unique for women —after the brain, the female reproductive system is the organ with the most endocannabinoid receptors in the human body.

Mor Applications

Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, providing end-to-end technology transfer services. Mor helps inventors to translate new ideas in the medical, pharmaceutical, diagnostics, medical IT and biotechnology fields into solutions available to health caregivers and patients.

Mor’s commercialization portfolio comprises over 100 different projects and companies in various stages of development, from pre-seed to advanced stage companies. The intellectual property is conceived and developed by professionals working at our 14 hospitals and around 2000 clinics across the country, including Beilinson, Meir, Kaplan, Carmel, Soroka, Ha-Emek, and Schneider medical centers.

NADYA clinic

The clinic of reproductive medicine NADIYA successfully helps people to become parents for over 13 years. More than 5084 children were born due to the treatment of infertility in the clinic by using advanced methods of assisted reproductive technology.

In 2017, DL-NADIYA consortium united the team of US and Ukrainian scientists who have combined experience in molecular genetics, embryology and human reproduction to develop the newest methods for achieving the pregnancy with a healthy baby in women with the high risk of mitochondrial pathology in their offspring, as well as in complicated cases of infertility forms with high genetic risk.